Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.

HCM

HUTCHMED China (HCM)

HUTCHMED China Limited
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:HCM
DateTimeSourceHeadlineSymbolCompany
24/09/202420:09Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:HCMHUTCHMED China Limited
24/09/202417:00GlobeNewswire Inc.HUTCHMED Announces Japan Approval for FRUZAQLA® (fruquintinib) Received by TakedaNASDAQ:HCMHUTCHMED China Limited
18/09/202401:22GlobeNewswire Inc.International companies to host live webcasts at Deutsche Bank’s Depositary Receipts Virtual Investor Conference on September 24th and 25th, 2024NASDAQ:HCMHUTCHMED China Limited
09/09/202410:00GlobeNewswire Inc.HUTCHMED Highlights Clinical Data to be Presented at ESMO Congress 2024 and the 2024 World Conference of Lung CancerNASDAQ:HCMHUTCHMED China Limited
30/08/202420:13Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:HCMHUTCHMED China Limited
30/08/202414:30GlobeNewswire Inc.HUTCHMED Provides Update on Fruquintinib for Second-Line Gastric Cancer in ChinaNASDAQ:HCMHUTCHMED China Limited
22/08/202420:10Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:HCMHUTCHMED China Limited
21/08/202420:07Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:HCMHUTCHMED China Limited
21/08/202418:30GlobeNewswire Inc.HUTCHMED to Host Expert Call to discuss Immune ThrombocytopeniaNASDAQ:HCMHUTCHMED China Limited
31/07/202421:13Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:HCMHUTCHMED China Limited
31/07/202421:00GlobeNewswire Inc.HUTCHMED Reports 2024 Interim Results and Provides Business UpdatesNASDAQ:HCMHUTCHMED China Limited
04/07/202410:00GlobeNewswire Inc.HUTCHMED Announces NDA Acceptance in China for Tazemetostat for the Treatment of Relapsed or Refractory Follicular Lymphoma with Priority Review StatusNASDAQ:HCMHUTCHMED China Limited
26/06/202418:30GlobeNewswire Inc.HUTCHMED to Announce 2024 Half-Year Financial ResultsNASDAQ:HCMHUTCHMED China Limited
24/06/202419:30GlobeNewswire Inc.Save the Date: HUTCHMED to Present R&D Updates on July 9, 2024NASDAQ:HCMHUTCHMED China Limited
22/06/202406:00GlobeNewswire Inc.HUTCHMED Announces European Commission Approval for FRUZAQLA® (fruquintinib) Received by TakedaNASDAQ:HCMHUTCHMED China Limited
17/06/202410:00GlobeNewswire Inc.HUTCHMED Highlights Publication of Phase III ESLIM-01 Results in The Lancet HaematologyNASDAQ:HCMHUTCHMED China Limited
07/06/202420:25Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:HCMHUTCHMED China Limited
07/06/202410:00GlobeNewswire Inc.HUTCHMED Initiates Phase I Trial of Menin Inhibitor HMPL-506 in Patients with Hematological Malignancies in ChinaNASDAQ:HCMHUTCHMED China Limited
03/06/202420:13Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:HCMHUTCHMED China Limited
03/06/202410:00GlobeNewswire Inc.HUTCHMED Highlights Publication of Phase III FRUTIGA Results in Nature MedicineNASDAQ:HCMHUTCHMED China Limited
31/05/202420:12Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:HCMHUTCHMED China Limited
24/05/202420:06Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:HCMHUTCHMED China Limited
24/05/202410:00GlobeNewswire Inc.HUTCHMED Highlights Presentations at the 2024 ASCO Annual MeetingNASDAQ:HCMHUTCHMED China Limited
18/05/202400:02Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:HCMHUTCHMED China Limited
18/05/202400:00GlobeNewswire Inc.HUTCHMED announces retirement of Chairman, appointment of new Chairman and change of members of board committeesNASDAQ:HCMHUTCHMED China Limited
17/05/202410:00GlobeNewswire Inc.HUTCHMED Highlights Sovleplenib Phase III ESLIM-01 Study and Hematological Malignancy Programs Data to be Presented at the upcoming EHA2024 CongressNASDAQ:HCMHUTCHMED China Limited
14/05/202410:00GlobeNewswire Inc.HUTCHMED Initiates the RAPHAEL Registrational Phase III Trial of HMPL-306 for Patients with IDH1- and/or IDH2-Mutated Relapsed/Refractory Acute Myeloid Leukemia in ChinaNASDAQ:HCMHUTCHMED China Limited
14/05/202410:00GlobeNewswire Inc.HUTCHMED Initiates Phase II/III Trial of the Combination of Surufatinib and Camrelizumab for Treatment-Naïve Pancreatic Ductal Adenocarcinoma in Collaboration with HengruiNASDAQ:HCMHUTCHMED China Limited
08/05/202418:30GlobeNewswire Inc.HUTCHMED Announces Appointment of Independent Non-executive Director and Member of Board CommitteeNASDAQ:HCMHUTCHMED China Limited
26/04/202422:30GlobeNewswire Inc.HUTCHMED Announces Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer Received by TakedaNASDAQ:HCMHUTCHMED China Limited
 Showing the most relevant articles for your search:NASDAQ:HCM

Your Recent History

Delayed Upgrade Clock